Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review
Purpose: Equitable inclusion of racial and ethnic participation in clinical trials is crucial to improving disparities in health care, especially for historically marginalized populations. Our study aims to describe the racial and ethnic demographics of patients enrolled in published phase 2 clinica...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Particle Therapy Co-operative Group
2023-05-01
|
| Series: | International Journal of Particle Therapy |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.14338/IJPT-22-00042.1 |
| _version_ | 1797660242062868480 |
|---|---|
| author | Jonathan S. Fakhry M. Juliana Pena Ariel Pomputius Fantine Giap, MD Raymond B. Mailhot Vega, MD |
| author_facet | Jonathan S. Fakhry M. Juliana Pena Ariel Pomputius Fantine Giap, MD Raymond B. Mailhot Vega, MD |
| author_sort | Jonathan S. Fakhry |
| collection | DOAJ |
| description | Purpose: Equitable inclusion of racial and ethnic participation in clinical trials is crucial to improving disparities in health care, especially for historically marginalized populations. Our study aims to describe the racial and ethnic demographics of patients enrolled in published phase 2 clinical trials involving proton therapy in the United States.
Materials and Methods: Published manuscripts were identified in PubMed, Embase, World of Science, and Cochrane. Phase 2 trials evaluating proton therapy for US patients were included. For each article in the study, data were collected comprising authors, title, and publication year, and clinical trial numbers were verified. Additional data included tumor site, primary institution, sample size, reported race/ethnicity, and raw number/percentile of race/ethnicity. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used.
Results: Overall, 970 titles were identified; 636 remained after duplicate screening, and 75 full-text articles were assessed. We identified 38 eligible manuscripts for inclusion comprising 2648 patients. Only 15 (39%) of the publications reported race/ethnicity. Of these, 8 (21%) and 10 (26%) documented Hispanic or Black trial participants, respectively; however, only 6 (16%) documented trial participation for both Hispanic and Black patients. Of the 1409 patients with a documented race/ethnicity, 89.0% (n = 1254) were non-Hispanic white, 5.3% (n = 75) were Black, and 2.2% (n = 31) were Hispanic. Other and unknown race/ethnicity comprised the remaining patients (3.5%; n = 49).
Conclusion: We identified underreporting of demographic data in published phase 2 proton therapy trials, which unfortunately mirrored underreporting for cancer drug clinical trials. We also noted dramatic Black and Hispanic patient underrepresentation across the trials in which race and ethnicity are reported. Findings highlight the urgent need to identify and address barriers to proton therapy trials for Black and Hispanic patients ensuring clinical trials in radiation oncology are representative of the patients seen in clinical practice. |
| first_indexed | 2024-03-11T18:27:55Z |
| format | Article |
| id | doaj.art-6ca57d42c8a74a6ea325b30a5c804061 |
| institution | Directory Open Access Journal |
| issn | 2331-5180 |
| language | English |
| last_indexed | 2024-03-11T18:27:55Z |
| publishDate | 2023-05-01 |
| publisher | Particle Therapy Co-operative Group |
| record_format | Article |
| series | International Journal of Particle Therapy |
| spelling | doaj.art-6ca57d42c8a74a6ea325b30a5c8040612023-10-13T14:07:13ZengParticle Therapy Co-operative GroupInternational Journal of Particle Therapy2331-51802023-05-01101515810.14338/IJPT-22-00042.1i2331-5180-10-1-51Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A ReviewJonathan S. Fakhry0M. Juliana Pena1Ariel Pomputius2Fantine Giap, MD3Raymond B. Mailhot Vega, MD41 Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA1 Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA2 University of Florida Health Science Center Libraries, Gainesville, FL, USA1 Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA1 Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USAPurpose: Equitable inclusion of racial and ethnic participation in clinical trials is crucial to improving disparities in health care, especially for historically marginalized populations. Our study aims to describe the racial and ethnic demographics of patients enrolled in published phase 2 clinical trials involving proton therapy in the United States. Materials and Methods: Published manuscripts were identified in PubMed, Embase, World of Science, and Cochrane. Phase 2 trials evaluating proton therapy for US patients were included. For each article in the study, data were collected comprising authors, title, and publication year, and clinical trial numbers were verified. Additional data included tumor site, primary institution, sample size, reported race/ethnicity, and raw number/percentile of race/ethnicity. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used. Results: Overall, 970 titles were identified; 636 remained after duplicate screening, and 75 full-text articles were assessed. We identified 38 eligible manuscripts for inclusion comprising 2648 patients. Only 15 (39%) of the publications reported race/ethnicity. Of these, 8 (21%) and 10 (26%) documented Hispanic or Black trial participants, respectively; however, only 6 (16%) documented trial participation for both Hispanic and Black patients. Of the 1409 patients with a documented race/ethnicity, 89.0% (n = 1254) were non-Hispanic white, 5.3% (n = 75) were Black, and 2.2% (n = 31) were Hispanic. Other and unknown race/ethnicity comprised the remaining patients (3.5%; n = 49). Conclusion: We identified underreporting of demographic data in published phase 2 proton therapy trials, which unfortunately mirrored underreporting for cancer drug clinical trials. We also noted dramatic Black and Hispanic patient underrepresentation across the trials in which race and ethnicity are reported. Findings highlight the urgent need to identify and address barriers to proton therapy trials for Black and Hispanic patients ensuring clinical trials in radiation oncology are representative of the patients seen in clinical practice.https://theijpt.org/doi/pdf/10.14338/IJPT-22-00042.1proton therapyracedemographicsphase 2 trial |
| spellingShingle | Jonathan S. Fakhry M. Juliana Pena Ariel Pomputius Fantine Giap, MD Raymond B. Mailhot Vega, MD Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review International Journal of Particle Therapy proton therapy race demographics phase 2 trial |
| title | Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review |
| title_full | Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review |
| title_fullStr | Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review |
| title_full_unstemmed | Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review |
| title_short | Racial and Ethnic Demographic Reporting in Phase 2 Proton Therapy Clinical Trials: A Review |
| title_sort | racial and ethnic demographic reporting in phase 2 proton therapy clinical trials a review |
| topic | proton therapy race demographics phase 2 trial |
| url | https://theijpt.org/doi/pdf/10.14338/IJPT-22-00042.1 |
| work_keys_str_mv | AT jonathansfakhry racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview AT mjulianapena racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview AT arielpomputius racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview AT fantinegiapmd racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview AT raymondbmailhotvegamd racialandethnicdemographicreportinginphase2protontherapyclinicaltrialsareview |